Thursday, April 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking with Mr. Zach Baron, Director of the Health Policy and the Law Initiative at the O’Neill Institute

Launched in February 2023, the Health Care Litigation Tracker is a free digital resource that tracks and analyzes health care litigation in the United States. The tracker contains current health policy litigation cases, with an emphasis on health care access, coverage, affordability, transparency, and equity.

Zachary Baron is a director of the Health Policy and the Law Initiative at the O’Neill Institute. He focuses on providing technical assistance for policymakers and public education on health policy legal issues with an emphasis on access to coverage, affordability, transparency, and equity.

Cases discussed in the conversation are:

American College of Pediatricians et al. v. Becerra et al.

https://litigationtracker.law.georgetown.edu/litigation/american-college-of-pediatricians-et-al-v-becerra-et-al-2/

Barrows et al v. Humana, Inc.

https://litigationtracker.law.georgetown.edu/litigation/barrows-et-al-v-humana-inc/

Eli Lilly and Company et al. v. U.S. Department of Health and Human Services et al.

https://litigationtracker.law.georgetown.edu/litigation/eli-lilly-and-company-et-al-v-u-s-department-of-health-and-human-services-et-al/

 

#health #law #oneillinstitute #georgetown #policy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!